NDRA's TAEUS Device Achieves MRI-Level Liver Imaging Precision

ENDRA Life Sciences NDRA recently announced positive findings from a clinical study assessing the measurement consistency of its TAEUS Liver device. The evaluation demonstrated strong intra-operator repeatability and inter-operator reproducibility, underscoring the platform’s reliability for longitudinal monitoring of Steatotic Liver Disease (SLD).

The results are favorable in the context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition estimated to impact around 30% of the global adult population. The data support the device’s potential utility as a dependable point-of-care tool for disease assessment and management.

Validating Measurement Reliability in MASLD Monitoring

The clinical study evaluated 14 subjects under real-world conditions, with independent operators performing multiple scans to assess system performance. A total of 56 measurements were analyzed using Gage Repeatability and Reproducibility (R&R) methodology, which determines how much observed variability stems from the device itself versus actual biological differences.

TAEUS Liver achieved an Intraclass Correlation Coefficient (ICC) of 0.89 and a Standard Error of Measurement (SEM) of 3.3%, placing performance within the “Good to Excellent” reliability range. These metrics are important in MASLD, where detecting small, incremental changes in liver fat is essential for treatment monitoring and clinical decision-making.

Bridging the Gap Between MRI Precision and Accessibility

While MRI-PDFF remains the gold standard for liver fat quantification, its high cost, limited availability and infrastructure requirements restrict widespread use — particularly for frequent monitoring. NDRA’s TAEUS platform aims to bridge this gap by delivering MRI-comparable quantitative assessment in a more accessible, ultrasound-based format deployable at the point of care.

TAEUS’ performance contrasts with conventional ultrasound techniques, which are often limited by operator dependency and subjective interpretation. ENDRA’s thermoacoustic biomarker imaging approach is designed to reduce variability and standardize liver fat assessment, addressing a longstanding limitation in non-invasive liver diagnostics.

Strategic and Market Implications

The data strengthen NDRA’s regulatory and commercial outlook, as consistent measurements are essential for diagnostic approval and treatment monitoring. For clinicians, a reliable point-of-care tool could support earlier intervention and frequent follow-up, while offering a cost-effective option for patient screening.

As new metabolic therapies emerge, the ability to measure changes in liver fat without repeated MRI scans may become valuable. If adoption scales, TAEUS could align with broader healthcare trends favoring decentralized diagnostics, cost containment and outpatient access. Overall, the study reinforces ENDRA’s strategy of combining MRI-level quantitative precision with the practical deployment advantages of ultrasound-based systems — positioning the company to address a large and underserved global patient population.

Peers in Liver Imaging & Interventional Care

The liver imaging and interventional care space continues to witness strategic innovation from major MedTech players such as GE HealthCare Technologies Inc. GEHC, Koninklijke Philips PHG and Medtronic plc MDT, each advancing differentiated technologies to address the growing global burden of liver disease.

GE HealthCare has introduced the next generation of its LOGIQ ultrasound portfolio — including the LOGIQ E10 Series, LOGIQ Fortis and LOGIQ Totus — built on Verisound Digital architecture with AI-powered workflow enhancements in February 2026. The portfolio introduces Ultrasound-Guided Fat Fraction, a new tool to evaluate liver fat content.

GE HealthCare’s LOGIQ E10 Series emphasizes scalable performance for high-volume departments and research environments, while LOGIQ Fortis delivers a compact, all-in-one system for diverse care settings. LOGIQ Totus extends portability with AI-driven decision support. Together, the portfolio reflects GEHC’s strategy to position ultrasound as a frontline, cost-efficient modality for liver assessment, aligning advanced quantification tools with workflow optimization and broader outpatient adoption trends.

Koninklijke Philips offers a comprehensive liver ultrasound platform combining image quality, quantification tools and workflow support. Core innovations include PureWave transducer technology for enhanced penetration and resolution, ElastQ for real-time tissue stiffness assessment and Liver Fat Quantification tools for measuring steatosis during standard exams. Auto ElastQ further improves consistency in elastography by assisting with optimal frame and ROI selection.

Koninklijke Philips also integrates Fusion and Navigation capabilities, enabling co-registration of CT, MR or PET imaging with live ultrasound in under one minute — enhancing lesion assessment and interventional planning. This multimodal approach positions Philips as a workflow partner, supporting diagnostic confidence, procedural planning and disease monitoring. The strategy aligns with increasing demand for non-invasive, reproducible tools in liver disease management.

Medtronic continues to expand precision in liver tumor ablation with the Emprint HP ablation generator powered by Thermosphere technology. The system enables partial or complete ablation of nonresectable liver tumors through a minimally invasive approach. Medtronic’s Emprint HP platform delivers up to 40% greater ablation volume while maintaining a predictable spherical shape and consistent margins greater than 5 mm. This supports high procedural accuracy and flexibility in antenna placement.

Compatible percutaneous antennas available in multiple lengths enhance adaptability across patient anatomies. By enabling large, controlled ablation zones while preserving healthy liver parenchyma, MDT positions the Emprint platform as a strategic option in comprehensive liver cancer management.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.

See

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Koninklijke Philips N.V. (PHG): Free Stock Analysis Report

Medtronic PLC (MDT): Free Stock Analysis Report

ENDRA Life Sciences Inc. (NDRA): Free Stock Analysis Report

GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research